Clinical Trial

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis. The main questions it will answer are: * Is there an impact on the severity and area of atopic dermatitis when participants take ENV-294 * What medical problems do participants have when taking ENV-294 Participants will: * Take drug ENV-294 or a placebo once every day for 12 weeks * Visit the clinic every 2 to 4 weeks for checkups and tests * Keep a diary of their symptoms and when they took their study drug * Return to the clinic for the final study visit at approximately week 16
Protocol Amendment History 4 changes
notable Trial sites expanded: 23 -> 32 locations 2026-07-30
notable Trial sites expanded: 20 -> 23 locations 2026-06-05
notable Trial sites expanded: 17 -> 20 locations 2026-05-13
notable Trial sites expanded: 12 -> 17 locations 2026-04-04
Trial Details
NCT Number NCT07298395
Lead Sponsor Enveda Therapeutics
Conditions Atopic Dermatitis (AD)
Enrollment 60 participants
Start Date 2025-12-22
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-29